On Wednesday, Shares of General Mills, Inc. (NYSE:GIS), gained 1.08% to $59.18.
General Mills, stated results for the second quarter of fiscal 2016.
Second Quarter Results Summary
- Net sales declined 6 percent to $4.42 billion, counting a 1 point decline from acquisitions and divestitures. On a constant-currency basis, net sales declined 2 percent.
- Total segment operating profit totaled $839 million, down 1 percent. In constant currency, total segment operating profit raised 2 percent.
- Diluted earnings per share (EPS) totaled 87 cents contrast to 56 cents a year ago.
- Adjusted diluted EPS, which excludes certain items affecting comparability of results, totaled 82 cents in the second quarter of 2016, up 2 percent. On a constant-currency basis, adjusted diluted EPS raised 5 percent.
General Mills Chairman and Chief Executive Officer Ken Powell said, “Our second-quarter results put us in line with our expectations at the midway point in our fiscal year. Constant-currency net sales declined modestly in the quarter, due in part to the divestiture of our North American Green Giant business. Our adjusted gross margin raised for the third successive quarter, which, combined with our continued cost savings efforts, assisted drive mid single-digit constant-currency growth in adjusted diluted EPS. Through six months, we’ve posted 1 percent growth in net sales and double-digit growth in segment operating profit and adjusted diluted EPS, each in constant currency.”
General Mills, Inc. manufactures and markets branded consumer foods in the United States and internationally. It also supplies branded and unbranded food products to the foodservice and commercial baking industries.
Shares of Walgreens Boots Alliance Inc (NASDAQ:WBA), inclined 3.17% to $84.71, during its last trading session.
Looking to bring joy to someone who makes a difference in your daily life? Whether it’s a gift for the crossing guard who ensures your child makes it safely across the street or the mail carrier who is never deterred by rain, sleet or snow, Walgreens is making it easy to find small, thoughtful gifts that spread unpredictable joy this holiday season. And to better serve its customers during the holidays, Walgreens stores are open until midnight or later through Dec. 24to assist shoppers cut down on the holiday hassle.
- Starting Dec. 14 through Christmas Eve, all non-24 hour stores will be open until midnight and 24 hour stores will remain open around the clock. Pharmacy hours will not change.
- On Christmas Day, all non-24 hour stores will be open from 8 a.m. to 10 p.m. and 24 hour stores will remain open all day. Pharmacy hours will vary by location.
- Customers also can order gifts on Walgreens.com until 11:59 p.m. on Dec. 21 to receive items by Christmas Eve.
“This is the time of year to spread joy to the ones we care about and appreciate. With a broad product assortment, and many available for under $25, we make it easy to find small thoughtful gifts,” said Moe Alkemade, group vice president of competitive convenience for Walgreens. “Whether it’s a hot new beauty product for that perfect stocking stuffer, a delicious box of candy for a party host, or a last-minute gift card, our dedicated team members are standing by to assist you find the perfect gift that will bring joy to others this holiday.”
Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, counting non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.
Finally, AbbVie Inc (NYSE:ABBV), ended its last trade with 2.18% gain, and closed at $57.62.
AbbVie (ABBV) will take part in the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016. Richard A. Gonzalez, chairman and chief executive officer, will make a formal presentation on the company at 10:30 a.m. Central time.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The companys products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.